FDA approves Gilead’s latest HIV treatment
April 5, 2016Manufacturing and Production, Research and Development Gilead, HIV, descovy, taf, taf-based, therapy
Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration has approved their TAF-based HIV therapy, Descovy (emtricitabine, …
Gilead to buy Nimbus Therapeutics’ unit, trial drug for up to $1.2 billion
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Gilead Sciences, M&A, MA, Nimbus Apollo, Nimbus Therapeutics, merger and acquisitions
Gilead Sciences (Nasdaq: GILD) has agreed to buy a unit of biotechnology firm Nimbus Therapeutics and its trial drug to …
Janssen and Genmab sued for patent infringement in US
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, darzalex, morphosys, patent infringement
German biotech company, Morphosys, is suing Janssen and Genmab for alleged patent infringement in their oncology drug, Darzalex (daratumumab).
Outsourcing and Robots: how smart pharmas are optimising R&D operations
April 5, 2016Manufacturing and Production
Faced with steadily rising research and development costs, as well as increasingly stringent regulatory requirements, pharmaceutical firms are re-evaluating their …
Anika Therapeutics names CMO, COO
April 4, 2016Sales and Marketing Anika Therapeutics, CMO, COO, Executive appointment
Anika Therapeutics (Nasdaq: ANIK) on Monday named the executive appointments of Stephen Mascioli the chief medical officer (CMO) and Dana …
Eisai’s Halaven recommended for European approval
April 4, 2016Research and Development, Sales and Marketing Eisai, Halaven, liposarcoma
Eisai has received a positive opinion from the European Commission’s CHMP for Halaven (eribulin) as a second-line therapy for patients …
Weekly Movers: Lupin, Natco Pharma, Keryx, Puma Biotech
April 4, 2016Research and Development, Sales and Marketing
Another week of big gains and some major losses has come to pass. While the Indian pharma sector continues to …
Research shows Novartis’s Entresto reduces cardiovascular death and heart failure
April 4, 2016Research and Development, Sales and Marketing Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent
Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure …
Takeda, Teva name Hiroshi Matsumori CEO of Japanese generic drug joint venture
April 4, 2016Business Services, Sales and Marketing CEO Appointment, Takeda, Teva, joint venture
Japanese drug firm Takeda (TYO: 4502) and Israel-based Teva (NYSE: TEVA) named Hiroshi Matsumori the chief executive for their newly-formed …
Amicus Therapeutics’ Fabry disease drug gets European regulatory support
April 4, 2016Research and Development, Sales and Marketing Amicus Therapeutics, EMA, Fabry disease, genetic disorder, rare disease
Shares in biotechnology firm Amicus Therapeutics (Nasdaq: FOLD) rose to close up nearly 3% after the European regulators announced backing …
Novo says Victoza bests MSD’s Januvia at lowering blood sugar
April 4, 2016Research and Development Novo Nordisk, Victoza
Novo Nordisk says its diabetes drug Victoza, in combination with metformin, outperformed MSD’s Januvia plus metformin in reducing HbA1c – …
Amgen’s high cholesterol drug at centre of patent court case yields positive clinical trial results
April 4, 2016Research and Development, Sales and Marketing Amgen, Repatha, Sanofi, high cholesterol. ldl, ldl-c, phase III, statins
Amgen has announced positive results from the Phase III GAUSS-3 clinical trial evaluating Repatha (evolucumab) in patients with high cholesterol …
GSK’s gene therapy for rare condition in children gets EMA backing
April 4, 2016Research and Development, Sales and Marketing ADA-SCID, European Medicines Agency, GlaxoSmithKline, Orphan Therapy, Rare Treatment, drug trial, gene therapy
UK drug major GlaxoSmithKline (LSE: GSK) has won marketing recommendation from European regulators for its first gene therapy to treat …
Timeline of turmoil – Valeant Pharmaceuticals’ troubled March 2016
April 4, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Share price, Valeant, fall, month from hell, timeline, turmoil
As far as months go, March 2016 couldn’t have gone much worse for Valeant Pharmaceuticals. The Canada-based company has been …
Two CHMP nods for Janssen
April 4, 2016Research and Development, Sales and Marketing Xeplion, darzalex, multiple myeloma
The European Commission’s scientific committee has recommended Janssen’s Darzalex (daratumumab) for multiple myeloma and Trevicta (paliperidone palmitate) for maintenance treatment …
Sanofi’s dengue vaccine rolled out for world’s first public immunisation program
April 4, 2016Sales and Marketing Philippines, Sanofi, Vaccine, children, dengue, dengvaxia, immunisation, prevention, public health
Sanofi, along with its vaccines global business unit Sanofi Pasteur, has announced the beginning of the first public dengue immunisation …
Daiichi Sankyo names Antoine Yver global head of oncology research and development
April 1, 2016Business Services, Medical Communications Daiichi Sankyo, Japan, appointment
Japanese drug major Daiichi Sankyo (TYO: 4568) on Friday named Antoine Yver, global head, oncology research and development, effective April …
Pfizer’s cholesterol-lowering bococizumab shows promise in Phase III trials
April 1, 2016Research and Development, Sales and Marketing Pfizer, bococizumab, lipid, phase 3, phase III, spire, spire-ai
Pfizer (NYSE: PFE) has announced positive top line results from the SPIRE-AI Phase III clinical trial evaluating bococizumab. This protein …
FTC files complaint against Endo for blocking generics of its pain drugs
April 1, 2016Business Services, Manufacturing and Production, Medical Communications, Sales and Marketing Endo International, FTC, legal, regulation
The US Federal Trade Commission (FTC) has filed a complaint against Endo International (Nasdaq: ENDP) alleging the company used illegal …
FDA to review investigational hepatitis B vaccine
April 1, 2016Medical Communications, Research and Development dynavax, hepatitis B, vaccines
Dynavax Technologies (NASDAQ: DVAX) says the FDA has accepted for review the company’s investigational adult hepatitis B vaccine, HEPLISAV-B. The FDA has set …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
